Spots Global Cancer Trial Database for Tanespimycin in Treating Women With Refractory Locally Advanced or Metastatic Breast Cancer

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Tanespimycin in Treating Women With Refractory Locally Advanced or Metastatic Breast Cancer

Official Title: A Phase II Clinical Trial of 17-Allyamino-17-Demethoxygeldanamycin (17-AAG) in Chemotherapy Refractory Metastatic Breast Cancer

Study ID: NCT00096109

Conditions

Recurrent Breast Cancer

Stage IIIB Breast Cancer

Stage IIIC Breast Cancer

Stage IV Breast Cancer

Interventions

tanespimycin

laboratory biomarker analysis

Study Description

Brief Summary: This phase II trial is studying how well tanespimycin works in treating women with refractory locally advanced or metastatic breast cancer. Drugs used in chemotherapy, such as tanespimycin, work in different ways to stop tumor cells from dividing so they stop growing or die

Detailed Description: PRIMARY OBJECTIVES: I. To determine the response rate of 17-Allylamino-17-Demethoxygeldanamycin (17-AAG) (tanespimycin) in patients with refractory/resistant metastatic breast cancer. II. To determine the progression free survival (PFS) of patients with refractory/resistant metastatic breast cancer when treated with 17-AAG. III. To correlate patients' her2/neu status with response to 17-AAG treatment. OUTLINE: This is a multicenter study. Patients receive tanespimycin IV over 1-6 hours on days 1, 4, 8, and 11. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients are followed at day 30, every 10-12 weeks until disease progression, and then every 3 months thereafter.